SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst a fervent debate over Bitcoin's near-term price direction, with discussions highlighting recent ETF outflows and broader market dynamics. The community remains sharply divided, as many anticipate a "parabolic" rally for Bitcoin as a hedge against inflation, while others warn of an impending "crypto winter" and significant price corrections based on historical cycles and perceived lack of intrinsic value.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF ($ETHA) is a hot topic due to Ethereum's upcoming Fusaka upgrade and increasing institutional appetite for staked Ethereum ETFs. The community is actively discussing ETHA's role as a foundational asset for tokenization, with many seeing current price action as a prime opportunity to accumulate, anticipating significant long-term growth.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

VRDN is trending as community members discuss recent analyst upgrades citing a differentiated profile relative to existing treatments for Thyroid Eye Disease (TED). The potential for M&A activity in 2026 is also fueling conversation, with some speculating on buyout prices. Community members are weighing the company's financial position, upcoming data readouts, and commercial launch plans in their analysis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR) Short Interest Update

Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR - Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest...

Grupo Aeroportuario del Sureste (NYSE:ASR) Share Price Passes Above 200-Day Moving Average - Time to Sell?

Grupo Aeroportuario del Sureste (NYSE:ASR) Shares Cross Above 200-Day Moving Average - Here's What Happened...

ABS Direct Equity Fund LLC Purchases Shares of 11,140 Grupo Aeroportuario del Sureste, S.A. de C.V. $ASR

ABS Direct Equity Fund LLC acquired a new position in shares of Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR - Free Report) in the 3rd quarter, according to the company in its most recent...

ASUR Completes Acquisition of URW Airports, Expanding to Major U.S. Airport Hubs

ASUR Completes Acquisition of URW Airports, Expanding to Major U.S. Airport Hubs ASUR Completes Acquisition of URW Airports, Expanding to Major U.S. Airport Hubs PR Newswire MEXICO CITY, Dec. 11...

ASUR Announces Total Passenger Traffic for November 2025

ASUR Announces Total Passenger Traffic for November 2025 ASUR Announces Total Passenger Traffic for November 2025 PR Newswire MEXICO CITY, Dec. 8, 2025 Passenger traffic increased year-over-year by...

Grupo Aeroportuario del Sureste (NYSE:ASR) Upgraded to "Sector Outperform" at Scotiabank

Scotiabank raised shares of Grupo Aeroportuario del Sureste from a "sector perform" rating to a "sector outperform" rating in a research note on Thursday...

Hsbc Holdings PLC Lowers Stock Holdings in Grupo Aeroportuario del Sureste, S.A. de C.V. $ASR

Hsbc Holdings PLC reduced its stake in Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR - Free Report) by 65.6% during the second quarter, according to the company in its most recent 13F...

Quadrature Capital Ltd Has $1.68 Million Stock Holdings in Grupo Aeroportuario del Sureste, S.A. de C.V. $ASR

Quadrature Capital Ltd boosted its holdings in shares of Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR - Free Report) by 219.4% during the second quarter, according to its most recent 13F...

Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR) Receives Consensus Rating of "Reduce" from Brokerages

Shares of Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR - Get Free Report) have been given an average rating of "Reduce" by the seven analysts that are presently covering the stock...

Grupo Aeroportuario del Sureste (NYSE:ASR) Shares Gap Down - Should You Sell?

Grupo Aeroportuario del Sureste (NYSE:ASR) Shares Gap Down - Time to Sell...

Grupo Aeroportuario del Sureste SA de CV is a holding company, which engages in the operation, maintenance, and development of airports It operates through the following segments: Cancun, Aerostar, Airplan, Villahermosa, Merida, Holding and Services, and Other. The company was founded in 1996 and is headquartered in Mexico City, Mexico.

ASR
Grupo Aeroportuario Del Sureste SA de CV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ASR News

ASRGrupo Aeroportuario Del Sureste SA de CV